Scribble

GILD Stock Quote Price and Forecast | CNN

GILD

Gilead Sciences, Inc.

Key terms

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Nov 21 10:25am ET Gilead price target raised to $96 from $70 at UBS by TipRanks Nov 21 6:51am ET Gilead price target raised to $100 from $90 at Mizuho by TipRanks Nov 21 6:35am ET Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program by TipRanks Nov 19 9:55am ET Gilead price target raised to $100 from $85 at Argus by TipRanks Nov 18 7:47am ET Gilead price target raised to $84 from $81 at RBC Capital by TipRanks Nov 18 6:48am ET RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD) by TipRanks Nov 18 6:05am ET Ideaya Biosciences appoints Stu Dorman as chief commercial officer by TipRanks Nov 15 11:10am ET Gilead announces data from interim analysis of Phase 3 ASSURE study by TipRanks Nov 14 6:50pm ET Wolfe Research starts Gilead at Outperform on ‘multiple shots on goal’ by TipRanks Nov 14 4:16pm ET Gilead initiated with an Outperform at Wolfe Research by TipRanks Nov 14 7:36am ET Gilead Sciences (GILD) Gets a Buy from TD Cowen by TipRanks Nov 13 4:22pm ET Gilead initiated with a Buy at Citi by TipRanks Nov 13 6:50am ET Gilead reports results from pivotal Phase 3 PURPOSE 2 trial by TipRanks Nov 11 4:35pm ET JMP Securities healthcare analysts hold an analyst/industry conference call by TipRanks Nov 08 10:11am ET Gilead price target raised to $95 from $85 at TD Cowen by TipRanks Nov 08 10:10am ET Gilead price target raised to $97 from $83 at Truist by TipRanks Nov 08 9:25am ET Gilead price target raised to $103 from $95 at Raymond James by TipRanks Nov 08 8:33am ET Gilead cut to Hold at Maxim on valuation by TipRanks Nov 08 7:56am ET Gilead downgraded to Hold from Buy at Maxim by TipRanks Nov 08 2:31am ET Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating by TipRanks Nov 07 9:55am ET Early notable gainers among liquid option names on November 7th by TipRanks Nov 07 9:30am ET Gilead to present HIV research findings at conference by TipRanks Nov 07 8:49am ET Gilead price target raised to $80 from $70 at Cantor Fitzgerald by TipRanks Nov 07 8:19am ET Cantor Fitzgerald Sticks to Its Hold Rating for Gilead Sciences (GILD) by TipRanks Nov 07 8:11am ET Gilead price target raised to $105 from $95 at Oppenheimer by TipRanks Nov 07 7:46am ET Gilead price target raised to $105 from $95 at Piper Sandler by TipRanks Nov 07 7:46am ET Gilead price target raised to $102 from $94 at BMO Capital by TipRanks Nov 07 6:50am ET Gilead price target raised to $95 from $80 at Baird by TipRanks Nov 07 6:47am ET RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD) by TipRanks Nov 07 6:41am ET Gilead Sciences (GILD) Gets a Buy from Piper Sandler by TipRanks Nov 07 6:38am ET Balanced Outlook on Gilead Sciences Amid Strong Q3 Results and Growth Uncertainties by TipRanks

Nov 22 1:37pm ET Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics by Zacks Nov 20 11:00am ET GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study by Zacks Nov 19 9:19am ET ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs by Zacks Nov 18 3:00pm ET FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria by Zacks Nov 18 9:49am ET Eyenovia Stock Tumbles on Termination of Phase III Myopia Study by Zacks Nov 18 9:26am ET ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study by Zacks Nov 14 9:30am ET Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet by Zacks Nov 14 9:00am ET Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know by Zacks Nov 13 6:20am ET Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now? by Zacks Nov 12 11:40am ET GILD or VRTX: Which Is the Better Value Stock Right Now? by Zacks Nov 11 1:50pm ET Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell? by Zacks Nov 07 11:13am ET Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook by Zacks Nov 06 6:10pm ET Markets Tear Off the Lid in Hump-Day Trading by Zacks Nov 06 6:00pm ET Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say by Zacks Nov 06 5:15pm ET Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates by Zacks Nov 06 10:48am ET Pre-Markets Soar after Trump Wins U.S. Presidential Election by Zacks Nov 06 10:12am ET Pre-Markets Surge on Historic Trump Victory by Zacks Nov 06 9:56am ET Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow by Zacks Nov 05 3:00pm ET What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings? by Zacks Nov 04 1:43pm ET Gilead Science to Report Q3 Earnings: What's in the Cards? by Zacks Nov 01 9:15am ET Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics by Zacks Oct 31 5:50pm ET Gilead Sciences (GILD) Gains As Market Dips: What You Should Know by Zacks Oct 31 9:00am ET Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It by Zacks Oct 30 10:01am ET Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline by Zacks Oct 30 6:20am ET Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar? by Zacks Oct 29 6:00pm ET Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why by Zacks Oct 24 12:12pm ET Compugen Gears Up to Report Q3 Earnings: Here's What to Expect by Zacks Oct 24 11:49am ET Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More by Zacks Oct 23 6:00pm ET Why Gilead Sciences (GILD) Dipped More Than Broader Market Today by Zacks Oct 22 6:20am ET Should You Invest in the VanEck Biotech ETF (BBH)? by Zacks Oct 21 1:50pm ET Gilead, MRK Report Data From Investigational Combination Study for HIV by Zacks

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Target expects a sluggish holiday season.

David Paul Morris/Bloomberg/Getty Images

Target sounds the alarm bell on holiday shopping

Investors piled into safe havens like gold and US debt as tensions rose in Europe. Gold prices jumped on Tuesday and US Treasury rates dipped.

Angela Weiss/AFP/Getty Images

Stocks shrug off concerns about heightened US-Russia tensions

A lone shopper places items in her cart in the frozen food aisle of a Walmart store Thursday, Nov. 14, 2024, in Englewood, Colo.

David Zalubowski/AP

As Americans bargain shop, six-figure earners flock to Walmart

NEW YORK, NEW YORK - JULY 07: Bikes with Grubhub bags sit on the street on July 07, 2023 in New York City. Grubhub, DoorDash and Uber Eats sued the City of New York on July 6th in order to block its new minimum pay rules for food delivery workers. (Photo by Leonardo Munoz/VIEWpress)

Leonardo Munoz/VIEWpress/Getty Images

Grubhub just sold for $650 million. Four years ago it was worth $7.3 billion